Skip to Main content Skip to Navigation
Journal articles

Compared efficacy and safety of vedolizumab and infliximab in ulcerative colitis after failure of a first subcutaneous anti-TNF agent: a multicentre cohort study

Abstract : Background - Few data exist to help select a second biologic agent in patients with refractory ulcerative colitis (UC). Aim - To compare the efficacy of infliximab (IFX) and vedolizumab (VDZ) in UC patients who failed a first subcutaneous anti-tumor necrosing factor (TNF) agent. Methods - Consecutive UC patients from 12 French centres starting IFX or VDZ after at least one injection of adalimumab or golimumab have been included in a retrospective study. Outcomes were clinical remission at week 14, survival without treatment discontinuation and survival without UC-related event. Results - Among the 225 patients included, clinical remission at week 14 was achieved in 40/154 (26%) patients treated with IFX and in 35/71 (49%) treated with VDZ (P = 0.001). After a propensity score matching analysis, this difference remained significant (odds ratio: 1.67; 95% confidence interval: 1.08-2.56; P = 0.02). With a median follow-up of 117 weeks, survival rates without treatment discontinuation at years 1 and 3 were 50% and 29% with IFX, and 80% and 55% with VDZ, respectively (P < 0.001). Regarding survival without UC-related event, they were 49% and 27% with IFX, and 74% and 52% with VDZ (P < 0.01). Conclusion - After failure of a first subcutaneous anti-TNF agent, UC patients were more likely to achieve clinical remission with VDZ than those treated with IFX. Although due to prescription habits patients in the IFX group had a significantly more severe disease, these differences remained after adjustments and subgroup analyses. Such results have to be confirmed prospectively and warrant dedicated head-to-head trials.
Document type :
Journal articles
Complete list of metadatas

https://hal-univ-rennes1.archives-ouvertes.fr/hal-02562228
Contributor : Laurent Jonchère <>
Submitted on : Monday, May 4, 2020 - 2:53:39 PM
Last modification on : Tuesday, January 19, 2021 - 4:06:34 PM

Identifiers

Citation

Marianne Hupe, Pauline Riviere, Stephane Nancey, Xavier Roblin, Romain Altwegg, et al.. Compared efficacy and safety of vedolizumab and infliximab in ulcerative colitis after failure of a first subcutaneous anti-TNF agent: a multicentre cohort study. Alimentary Pharmacology and Therapeutics, Wiley, 2020, 51 (9), pp.852-860. ⟨10.1111/apt.15680⟩. ⟨hal-02562228⟩

Share

Metrics

Record views

38